https://padlet.com/dov_ballak/410t1ub2vzvd Made with joy en-us 2016-11-16 08:43:07 UTC 2016-11-16 11:25:41 UTC hello@padlet.com dov_ballak https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993419 2016-11-16 08:44:12 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993419 dov_ballak https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993426 2016-11-16 08:44:16 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993426 dov_ballak https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993445 2016-11-16 08:44:25 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993445 dov_ballak https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993480 2016-11-16 08:44:36 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993480 dov_ballak https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993529 2016-11-16 08:44:58 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/137993529 https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138023693 2016-11-16 11:17:03 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138023693 https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138023701 A total of 314 assesed for eligibility, and 256 women (138 in the enoxaparin group and 118 in the placebo group) completed the whole analyse. There's not observed any significant difference in secondary outcomes between the 2 groups. During the study, 30,4% of women in the enoxaparin group vs 23,7% in the placebo group had a subsequent miscarriage (relative risk 1.28: 95% CI, 0,85-1,93) occured before 10 weeks' gestation. Seven women developed thrombocytopenia. ]]> 2016-11-16 11:17:05 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138023701 https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138023714 We performed a multicenter, randomized, double-blinded placebo-controlled trial in which participants who were pregnant and had ≥ 2 miscarriages were included. We randomly assigned them to receive enoxaparin (n= 138) or a placebo (saline solution) (n=120) . Women were seen in a clinic every month until completion of the pregnancy, and one time 2 months post-delivery, by a medical investigator. The primary outcome was the rate of live and viable births. ]]> 2016-11-16 11:17:14 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138023714 https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138023786 2016-11-16 11:17:39 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138023786 https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138024070 Miscarriage, defined as a spontaneous loss of the conceptus before 20 weeks' gestation, is clinically detected in approximately 10% tot 15% of pregnancies and recurs in 5% of subsequent pregnancies. Standard investigations fail to reveal any apparent cause in >50% of the woman. Therefore, in 2006, we designed the PREFIX (Prevention of Unexplained Recurrent Abortion by Enoxaparin) study, a randomized double-blind, placebo-controlled multicenter trial to investigate whether LMWH would improve the live-birth rate among nonthrombophilic women. ]]> 2016-11-16 11:19:24 UTC https://padlet.com/dov_ballak/410t1ub2vzvd/wish/138024070